Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 12.10
NVO's Cash to Debt is ranked lower than
57% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. NVO: 12.10 )
Ranked among companies with meaningful Cash to Debt only.
NVO' s 10-Year Cash to Debt Range
Min: 0.29  Med: 9.95 Max: N/A
Current: 12.1
Equity to Asset 0.42
NVO's Equity to Asset is ranked lower than
76% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NVO: 0.42 )
Ranked among companies with meaningful Equity to Asset only.
NVO' s 10-Year Equity to Asset Range
Min: 0.42  Med: 0.66 Max: 0.73
Current: 0.42
0.42
0.73
Interest Coverage 884.41
NVO's Interest Coverage is ranked lower than
81% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NVO: 884.41 )
Ranked among companies with meaningful Interest Coverage only.
NVO' s 10-Year Interest Coverage Range
Min: 5.69  Med: 24.21 Max: 884.41
Current: 884.41
5.69
884.41
F-Score: 8
Z-Score: 16.33
M-Score: -2.35
WACC vs ROIC
13.23%
109.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 40.51
NVO's Operating margin (%) is ranked higher than
95% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. NVO: 40.51 )
Ranked among companies with meaningful Operating margin (%) only.
NVO' s 10-Year Operating margin (%) Range
Min: 10.5  Med: 23.85 Max: 38.84
Current: 40.51
10.5
38.84
Net-margin (%) 31.92
NVO's Net-margin (%) is ranked higher than
93% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. NVO: 31.92 )
Ranked among companies with meaningful Net-margin (%) only.
NVO' s 10-Year Net-margin (%) Range
Min: 11.39  Med: 17.53 Max: 30.13
Current: 31.92
11.39
30.13
ROE (%) 82.77
NVO's ROE (%) is ranked higher than
98% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. NVO: 82.77 )
Ranked among companies with meaningful ROE (%) only.
NVO' s 10-Year ROE (%) Range
Min: 11.85  Med: 21.58 Max: 63.92
Current: 82.77
11.85
63.92
ROA (%) 42.38
NVO's ROA (%) is ranked higher than
98% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. NVO: 42.38 )
Ranked among companies with meaningful ROA (%) only.
NVO' s 10-Year ROA (%) Range
Min: 8.5  Med: 14.78 Max: 37.03
Current: 42.38
8.5
37.03
ROC (Joel Greenblatt) (%) 163.36
NVO's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. NVO: 163.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 17.66  Med: 35.52 Max: 140.48
Current: 163.36
17.66
140.48
Revenue Growth (3Y)(%) 13.20
NVO's Revenue Growth (3Y)(%) is ranked higher than
70% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. NVO: 13.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -46.2  Med: 13.20 Max: 127.6
Current: 13.2
-46.2
127.6
EBITDA Growth (3Y)(%) 16.70
NVO's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. NVO: 16.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -44.6  Med: 16.40 Max: 130.7
Current: 16.7
-44.6
130.7
EPS Growth (3Y)(%) 18.80
NVO's EPS Growth (3Y)(%) is ranked higher than
77% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. NVO: 18.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVO' s 10-Year EPS Growth (3Y)(%) Range
Min: 0.8  Med: 20.30 Max: 37.2
Current: 18.8
0.8
37.2
» NVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

NVO Guru Trades in Q2 2014

Jim Simons 16,953,000 sh (+5.43%)
Ken Fisher 13,741,529 sh (+0.80%)
Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,740 sh (unchged)
Mario Gabelli 7,620 sh (-0.59%)
Ruane Cunniff 160,492 sh (-33.85%)
» More
Q3 2014

NVO Guru Trades in Q3 2014

Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,740 sh (unchged)
Ken Fisher 13,385,913 sh (-2.59%)
Jim Simons 16,106,100 sh (-5.00%)
Mario Gabelli 6,720 sh (-11.81%)
Ruane Cunniff 75,642 sh (-52.87%)
» More
Q4 2014

NVO Guru Trades in Q4 2014

Steven Cohen 481,700 sh (New)
Ruane Cunniff 82,192 sh (+8.66%)
Murray Stahl 7,907 sh (+2.16%)
Mario Gabelli 6,720 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Ken Fisher 13,039,648 sh (-2.59%)
Jim Simons 15,614,600 sh (-3.05%)
» More
Q1 2015

NVO Guru Trades in Q1 2015

Tom Gayner 1,075,000 sh (unchged)
Steven Cohen Sold Out
Ruane Cunniff 82,050 sh (-0.17%)
Mario Gabelli 6,700 sh (-0.30%)
Murray Stahl 7,740 sh (-2.11%)
Ken Fisher 12,660,235 sh (-2.91%)
Jim Simons 14,513,600 sh (-7.05%)
» More
» Details

Insider Trades

Latest Guru Trades with NVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 32.30
NVO's P/E(ttm) is ranked higher than
58% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 40.90 vs. NVO: 32.30 )
Ranked among companies with meaningful P/E(ttm) only.
NVO' s 10-Year P/E(ttm) Range
Min: 12.13  Med: 23.04 Max: 35.76
Current: 32.3
12.13
35.76
Forward P/E 24.45
NVO's Forward P/E is ranked lower than
52% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 23.87 vs. NVO: 24.45 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 32.30
NVO's PE(NRI) is ranked higher than
58% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 39.90 vs. NVO: 32.30 )
Ranked among companies with meaningful PE(NRI) only.
NVO' s 10-Year PE(NRI) Range
Min: 12.03  Med: 23.03 Max: 35.76
Current: 32.3
12.03
35.76
P/B 30.42
NVO's P/B is ranked lower than
95% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. NVO: 30.42 )
Ranked among companies with meaningful P/B only.
NVO' s 10-Year P/B Range
Min: 3.5  Med: 6.72 Max: 32.45
Current: 30.42
3.5
32.45
P/S 10.35
NVO's P/S is ranked higher than
52% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. NVO: 10.35 )
Ranked among companies with meaningful P/S only.
NVO' s 10-Year P/S Range
Min: 2.81  Med: 4.99 Max: 11.04
Current: 10.35
2.81
11.04
PFCF 35.35
NVO's PFCF is ranked higher than
56% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 41.97 vs. NVO: 35.35 )
Ranked among companies with meaningful PFCF only.
NVO' s 10-Year PFCF Range
Min: 12.07  Med: 23.97 Max: 47.01
Current: 35.35
12.07
47.01
POCF 30.52
NVO's POCF is ranked higher than
54% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 34.67 vs. NVO: 30.52 )
Ranked among companies with meaningful POCF only.
NVO' s 10-Year POCF Range
Min: 9.91  Med: 18.15 Max: 32.56
Current: 30.52
9.91
32.56
EV-to-EBIT 24.73
NVO's EV-to-EBIT is ranked higher than
58% of the 223 Companies
in the Global Biotechnology industry.

( Industry Median: 30.72 vs. NVO: 24.73 )
Ranked among companies with meaningful EV-to-EBIT only.
NVO' s 10-Year EV-to-EBIT Range
Min: 9.1  Med: 17.20 Max: 27.3
Current: 24.73
9.1
27.3
PEG 1.65
NVO's PEG is ranked higher than
71% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.75 vs. NVO: 1.65 )
Ranked among companies with meaningful PEG only.
NVO' s 10-Year PEG Range
Min: 0.54  Med: 1.19 Max: 1.87
Current: 1.65
0.54
1.87
Shiller P/E 47.73
NVO's Shiller P/E is ranked higher than
52% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 48.44 vs. NVO: 47.73 )
Ranked among companies with meaningful Shiller P/E only.
NVO' s 10-Year Shiller P/E Range
Min: 18.94  Med: 31.79 Max: 50.95
Current: 47.73
18.94
50.95
Current Ratio 1.04
NVO's Current Ratio is ranked lower than
87% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. NVO: 1.04 )
Ranked among companies with meaningful Current Ratio only.
NVO' s 10-Year Current Ratio Range
Min: 1.04  Med: 2.02 Max: 2.45
Current: 1.04
1.04
2.45
Quick Ratio 0.74
NVO's Quick Ratio is ranked lower than
88% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. NVO: 0.74 )
Ranked among companies with meaningful Quick Ratio only.
NVO' s 10-Year Quick Ratio Range
Min: 0.74  Med: 1.33 Max: 1.91
Current: 0.74
0.74
1.91
Days Inventory 272.73
NVO's Days Inventory is ranked lower than
85% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 116.21 vs. NVO: 272.73 )
Ranked among companies with meaningful Days Inventory only.
NVO' s 10-Year Days Inventory Range
Min: 201.98  Med: 304.77 Max: 417.53
Current: 272.73
201.98
417.53
Days Sales Outstanding 57.08
NVO's Days Sales Outstanding is ranked higher than
54% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.10 vs. NVO: 57.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVO' s 10-Year Days Sales Outstanding Range
Min: 45.09  Med: 52.94 Max: 152.61
Current: 57.08
45.09
152.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.32
NVO's Dividend Yield is ranked higher than
60% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. NVO: 1.32 )
Ranked among companies with meaningful Dividend Yield only.
NVO' s 10-Year Dividend Yield Range
Min: 0.79  Med: 1.52 Max: 2.47
Current: 1.32
0.79
2.47
Dividend Payout 0.44
NVO's Dividend Payout is ranked lower than
64% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 0.37 vs. NVO: 0.44 )
Ranked among companies with meaningful Dividend Payout only.
NVO' s 10-Year Dividend Payout Range
Min: 0.51  Med: 1.30 Max: 1.85
Current: 0.44
0.51
1.85
Dividend growth (3y) 46.20
NVO's Dividend growth (3y) is ranked higher than
92% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 6.30 vs. NVO: 46.20 )
Ranked among companies with meaningful Dividend growth (3y) only.
NVO' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 22.70 Max: 49.4
Current: 46.2
0
49.4
Yield on cost (5-Year) 6.26
NVO's Yield on cost (5-Year) is ranked higher than
93% of the 221 Companies
in the Global Biotechnology industry.

( Industry Median: 1.51 vs. NVO: 6.26 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVO' s 10-Year Yield on cost (5-Year) Range
Min: 3.74  Med: 7.20 Max: 11.7
Current: 6.26
3.74
11.7
Share Buyback Rate 2.60
NVO's Share Buyback Rate is ranked higher than
95% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. NVO: 2.60 )
Ranked among companies with meaningful Share Buyback Rate only.
NVO' s 10-Year Share Buyback Rate Range
Min: 49.1  Med: 2.20 Max: -92.3
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 31.78
NVO's Price/Tangible Book is ranked lower than
94% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. NVO: 31.78 )
Ranked among companies with meaningful Price/Tangible Book only.
NVO' s 10-Year Price/Tangible Book Range
Min: 3.14  Med: 6.09 Max: 32.07
Current: 31.78
3.14
32.07
Price/Projected FCF 4.73
NVO's Price/Projected FCF is ranked lower than
53% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. NVO: 4.73 )
Ranked among companies with meaningful Price/Projected FCF only.
NVO' s 10-Year Price/Projected FCF Range
Min: 1.41  Med: 3.01 Max: 160.48
Current: 4.73
1.41
160.48
Price/DCF (Earnings Based) 1.13
NVO's Price/DCF (Earnings Based) is ranked higher than
62% of the 13 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. NVO: 1.13 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 2.07
NVO's Price/Median PS Value is ranked lower than
76% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. NVO: 2.07 )
Ranked among companies with meaningful Price/Median PS Value only.
NVO' s 10-Year Price/Median PS Value Range
Min: 0.15  Med: 0.81 Max: 2.09
Current: 2.07
0.15
2.09
Price/Peter Lynch Fair Value 1.48
NVO's Price/Peter Lynch Fair Value is ranked higher than
68% of the 50 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. NVO: 1.48 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
NVO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.07  Med: 0.97 Max: 1.55
Current: 1.48
0.07
1.55
Price/Graham Number 6.80
NVO's Price/Graham Number is ranked lower than
79% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. NVO: 6.80 )
Ranked among companies with meaningful Price/Graham Number only.
NVO' s 10-Year Price/Graham Number Range
Min: 1.58  Med: 2.48 Max: 6.86
Current: 6.8
1.58
6.86
Earnings Yield (Greenblatt) (%) 4.00
NVO's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. NVO: 4.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.7  Med: 5.80 Max: 11
Current: 4
3.7
11
Forward Rate of Return (Yacktman) (%) 23.96
NVO's Forward Rate of Return (Yacktman) (%) is ranked higher than
70% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 14.58 vs. NVO: 23.96 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVO' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 1.7  Med: 21.90 Max: 35.6
Current: 23.96
1.7
35.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMGN, GILD, BIIB, CELG, CMXHY » details
Traded in other countries:0QIU.UK, NOVO B.Denmark, NOVA.Germany, NOVC.Germany, NOVOB.Switzerland, NONOF.USA,
Novo-Nordisk A/S is a healthcare company incorporated on November 28, 1931 in Denmark. The Company has diabetes product portfolios, including new generation insulins, a full portfolio of modern insulins as well as a human once-daily GLP-1 analog. In addition, it also has a position within haemophilia care, growth hormone therapy and hormone replacement therapy, and Company's first product to treat obesity, Saxenda, was approved in the United States in December 2014. The Company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. On December 23, 2014, the GLP-1 agonist liraglutide was approved in the United States in a 3 mg dose for weight management. The trade name for this product will be Saxenda and launch is planned for the first half of 2015. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. In 2014 the Company announced that all activities within inflammation will be discontinued. The Company's insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas. The important markets are North America, China, Japan and the major European countries. In addition there is an increasing contribution to its total sales from key markets in the sales region International Operations such as Algeria, Turkey, Australia, India, Argentina, Brazil and Russia.
» More Articles for NVO

Headlines

Articles On GuruFocus.com
Nintai Returns: Q2 2015 Jul 01 2015 
Leith Wheeler Investment Funds First Quarter 2015 Review Jun 15 2015 
Jim Simons' Top 3 Positions and One That Doubled Return Jun 10 2015 
Weekly 52-Week Highs Highlight: ALTR, AIG, LUX, NVO, EXPE May 03 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
Additional Changes to the Nintai Portfolio Apr 08 2015 
Probability and Magnitude in Investing Apr 02 2015 
Nintai Returns: Q1 2015 Apr 01 2015 
These High-Quality European Dividend Payers Could Benefit From A Rising Dollar Mar 18 2015 
To Reinvest or Not Reinvest: That is the Question Feb 19 2015 

More From Other Websites
Business Highlights Jul 02 2015
Novo Nordisk Halts Sale of Tresiba Insulin in Germany Over Pricing Dispute Jul 02 2015
The Greek debt crisis turned these European stocks into even better buys Jul 01 2015
Status regarding Novo Nordisk's holding of its own shares (30 June 2015) Jul 01 2015
Levemir® receives positive CHMP opinion for extended use in children as young as one year old Jun 26 2015
Conquering Hemophilia: Novo Nordisk Reports Encouraging Data From Phase III Trial Of NovoEight Jun 25 2015
Cramer: Getting down to BAX's Biz Jun 24 2015
In a phase 3 trial, NovoEight® provided long-term efficacy and safety in the prophylaxis and... Jun 24 2015
Fase 3-studie med NovoEight® viser langvarig effekt og sikkerhed ved forebyggelse og behandling af... Jun 24 2015
Novo Nordisk A/S - Aktietilbagekøbsprogram Jun 22 2015
Novo Nordisk A/S - Share repurchase programme Jun 22 2015
Edited Transcript of NOVO B.CO corporate analyst meeting Jun 17 2015
Novo Nordisk A/S upgraded by Morgan Stanley Jun 09 2015
Novo Nordisk Reveals New Findings from Additional Studies - Analyst Blog Jun 08 2015
Novo Nordisk A/S - Share repurchase programme Jun 08 2015
New Xultophy® (IDegLira) phase 3b study showed statistically significant HbA1c reduction, body... Jun 08 2015
Novo Nordisk A/S: New study with Victoza® (liraglutide) showed improvements in blood glucose... Jun 08 2015
Nyt fase 3b-studie med Xultophy® (IDegLira) viser statistisk signifikant reduktion i... Jun 08 2015
Novo Nordisk type 2 diabetes combo drug tops Sanofi's Lantus -study Jun 07 2015
New Xultophy® (IDegLira) Phase 3b Study Showed Statistically Significant HbA1c Reduction, Body... Jun 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK